Why Did Science Corp Recruit Yale's Top Neurosurgeon for BCI Leadership?
Science Corporation has appointed Murat Günel, MD, as Medical Director for Brain-Computer Interface programs, marking a significant clinical leadership addition for the company's visual prosthetics platform. Günel, who serves as Chair of Neurosurgery at Yale School of Medicine and Neurosurgeon-in-Chief at Yale New Haven Hospital, brings over two decades of clinical experience in neurovascular surgery and translational neuroscience to Science Corp's expanding BCI portfolio.
The appointment comes as Science Corp advances its Prima system—a subretinal photovoltaic chip designed to restore vision in patients with geographic atrophy from age-related macular degeneration. The company completed a successful 24-month feasibility study demonstrating sustained visual improvement in patients with severe vision loss, positioning the technology for potential FDA approval pathways. Günel's expertise in complex neurosurgical procedures and regulatory strategy will be critical as Science Corp prepares for larger pivotal trials expected to begin in 2026.
This leadership move signals Science Corp's commitment to clinical rigor as the visual prosthetics market intensifies, with competitors including Second Sight's Orion system and Pixium Vision's PRIMA competing for the estimated $3.2 billion addressable market for retinal implants by 2030.
Clinical Expertise Meets Cutting-Edge Neurotechnology
Günel's appointment addresses a critical gap in Science Corp's clinical leadership as the company transitions from feasibility studies to commercial-scale clinical trials. As Yale's neurosurgery chair since 2012, Günel has published over 400 peer-reviewed papers and led clinical trials in neurovascular interventions, giving him extensive experience with FDA Investigational Device Exemption (IDE) applications and regulatory frameworks essential for BCI device approval.
His research background in cerebrovascular biology and neural plasticity directly complements Science Corp's approach to visual restoration. The Prima system relies on photovoltaic stimulation of remaining retinal ganglion cells, requiring precise understanding of neural circuit adaptation—expertise Günel developed through his work on brain arteriovenous malformations and neural recovery mechanisms.
The timing of this appointment coincides with Science Corp's preparation for expanded clinical trials. The company's 24-month Prima study enrolled 38 patients across five clinical sites, demonstrating meaningful visual acuity improvements in 79% of participants. These results position Prima as a leading candidate for FDA Breakthrough Device Designation, a pathway Günel's regulatory experience could accelerate.
Strategic Implications for Visual BCI Market
Science Corp's recruitment of Günel represents a broader trend of established medical device companies hiring academic clinical leaders to navigate increasingly complex FDA pathways for neural interfaces. The appointment follows similar moves by Synchron, which recruited multiple neurosurgical advisors for its Endovascular BCI program, and Precision Neuroscience, which expanded its clinical advisory board with leading neurosurgeons.
For Science Corp, Günel's appointment strengthens its competitive position against Second Sight Medical Products, which has struggled with commercial adoption of its Argus II retinal prosthesis, and emerging competitors developing cortical visual prostheses. The visual BCI market has seen renewed investor interest following successful demonstrations of artificial vision systems, with total funding exceeding $150 million across all visual prosthetic platforms in 2025.
Günel's dual role as practicing neurosurgeon and clinical researcher positions Science Corp to accelerate patient enrollment and site activation for upcoming trials. His established relationships with major academic medical centers could prove crucial for the multi-site pivotal studies required for FDA approval, potentially reducing typical enrollment timelines from 18-24 months to 12-15 months.
The appointment also signals Science Corp's broader ambitions beyond retinal prostheses. The company has indicated interest in cortical visual interfaces and other sensory restoration platforms, areas where Günel's expertise in intracranial procedures and neural stimulation could prove valuable for future development programs.
Key Takeaways
- Science Corp appointed Yale neurosurgery chair Murat Günel as Medical Director for BCI programs
- Günel brings 20+ years of neurosurgical experience and extensive FDA regulatory expertise
- The appointment supports Science Corp's Prima retinal implant program advancing toward pivotal trials
- Science Corp's 24-month Prima study showed visual improvement in 79% of 38 enrolled patients
- The move strengthens Science Corp's position in the $3.2 billion visual prosthetics market
- Günel's academic network could accelerate patient enrollment for upcoming multi-site trials
Frequently Asked Questions
What is Science Corporation's Prima system and how does it work? Prima is a subretinal photovoltaic implant that converts light into electrical signals to stimulate remaining retinal ganglion cells in patients with geographic atrophy. The 2mm chip contains 378 photodiodes that generate neural stimulation without external power sources.
Why is Murat Günel's appointment significant for Science Corp? Günel brings extensive FDA regulatory experience, established relationships with academic medical centers, and deep expertise in neural stimulation—critical capabilities as Science Corp prepares for larger pivotal trials and potential commercial launch.
How does Science Corp's Prima compare to other visual prostheses? Prima targets the subretinal space with photovoltaic stimulation, while competitors like Second Sight focus on epiretinal approaches. Science Corp's 24-month data showing 79% response rates compares favorably to historical visual prosthetic outcomes.
What are the next steps for Science Corp's clinical development? The company is preparing expanded pivotal trials in 2026, with Günel's leadership expected to accelerate site activation and patient enrollment across multiple academic medical centers.
What does this appointment suggest about the visual BCI market? The recruitment of high-profile academic leaders indicates increasing competition and investment in visual prosthetics, as companies position for FDA approvals and commercial launches in the growing market for sensory restoration devices.